Serum Proteoglycans as Prognostic Biomarkers of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis

被引：70

作者：

Nault, Jean-Charles ^{[1
,4
,5
,6
]}

Guyot, Erwan ^{[2
,4
]}

Laguillier, Christelle ^{[2
,4
]}

Chevret, Sylvie ^{[7
,8
]}

Ganne-Carrie, Nathalie ^{[1
,4
]}

N'Kontchou, Gisele ^{[1
,4
]}

Beaugrand, Michel ^{[1
,4
]}

Seror, Olivier ^{[3
]}

Trinchet, Jean-Claude ^{[1
,4
]}

Coelho, Jessica ^{[1
,4
]}

Lasalle, Philippe ^{[10
]}

Charnaux, Nathalie ^{[2
,4
]}

Delehedde, Maryse ^{[10
]}

Sutton, Angela ^{[2
,4
]}

Nahon, Pierre ^{[1
,9
]}

机构：

[1] Hop Jean Verdier, AP HP, Serv Hepatol, Bondy, France

[2] Hop Jean Verdier, AP HP, Serv Biochim, Bondy, France

[3] Hop Jean Verdier, AP HP, Serv Radiol, Bondy, France

[4] Univ Paris 13, UFR SMBH, INSERM, U698, Bobigny, France

[5] INSERM, UMR 674, IUH, Paris, France

[6] Univ Paris 05, Fac Med, Labex Immunooncol, Sorbonne Paris Cite, Paris, France

[7] Hop St Louis, AP HP, Dept Biostat, Paris, France

[8] Univ Paris Diderot, INSERM, Unite Biostat & Epidemiol Clin, UMR S717, Paris, France

[9] Univ Paris 07, INSERM, Ctr Rech Bichat Beaujon CRB3, U773, Paris, France

[10] Inst Pasteur, Lille, France

来源：

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION | 2013年 / 22卷 / 08期

关键词：

ENDOCAN EXPRESSION; VASCULAR ENDOCAN; GROWTH-FACTOR; SYNDECAN-1; GLYPICAN-3; SURVIVAL; MARKER; MANAGEMENT; ESM-1;

D O I：

10.1158/1055-9965.EPI-13-0179

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Proteoglycans are involved in neoangiogenesis and transduction of oncogenic signals, two hallmarks of carcinogenesis. Methods: This study sought to assess the prognostic value of serum levels of three proteoglycans (endocan, syndecan-1, and glypican-3) and VEGF in 295 patients with alcoholic cirrhosis: 170 without hepatocellular carcinoma, 58 with early hepatocellular carcinoma, and 67 with advanced hepatocellular carcinoma at inclusion. We analyzed the association between proteoglycan levels and prognosis using Kaplan-Meier and Cox methods. Results: Serum levels of the three proteoglycans and VEGF were increased in patients with advanced hepatocellular carcinoma compared with those without hepatocellular carcinoma or with early hepatocellular carcinoma. In multivariate analysis, high levels of serum endocan (>5 ng/mL) were independently associated with death [HR, 2.84; 95% confidence interval (CI,) 1.18-6.84; P = 0.02], but not with hepatocellular carcinoma occurrence, in patients without hepatocellular carcinoma at baseline. High serum endocan (>5 ng/mL) and syndecan-1 (>50 ng/mL) levels were significantly associated with greater risk of tumor recurrence (P = 0.025) in patients with early hepatocellular carcinoma treated by radiofrequency ablation. In patients with advanced hepatocellular carcinoma, high serumlevels ofendocan (P = 0.004) andsyndecan-1 (P = 0.006) were significantly associated with less favorable overall survival. However, only a high level of serum syndecan-1 (>50 ng/mL) was independently associated with greater risk of death (HR, 6.21 95% CI, 1.90-20.30; P = 0.0025). Conclusion: Serum endocan and syndecan-1 are easily assessable prognostic serum biomarkers of overall survival in alcoholic cirrhosis with and without hepatocellular carcinoma. Impact: These new biomarkers will be useful to manage patients with hepatocellular carcinoma developed on alcoholic cirrhosis. (C) 2013 AACR.

引用

页码：1343 / 1352

页数：10

共 27 条

[1] Vascular endocan is preferentially expressed in tumor endothelium [J].